Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.

Clinical and translational science - 1 May 2025

Lteif Christelle, Gawronski Brian E, Cicali Emily J, Martinez Katherine A, Newsom Kimberly J, Starostik Petr, Cavallari Larisa H, Duarte Julio D

Abstract excerpt

Pharmacogenetic (PGx) testing can individualize pharmacotherapy, but many current panels lack inclusivity for diverse populations and are often cost-prohibitive for medically underserved communities. This study aimed to develop and validate GatorPGx Plus, a low-cost, preemptive PGx panel tailored for diverse patient populations. Pharmacogenes were selected based on the drug/drug classes potentially influenced by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CYP2C19 gene
Share to Gene Frequency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Precision Medicine

Share to Reproducibility of Results

Source

Open in PubMed Open full text

Identifiers

PMID: 40279185
DOI: 10.1111/cts.70230
PMCID: PMC12024485

Genes

CYP2C19

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.PMID 40279185Read ↗

Analytical and Clinical Validation of Action PharmaKitDx: A Comprehensive NGS Panel for the Identification of Pharmacogenetic Variants in Diverse PopulationsSemantic proximity Read ↗

Comprehensive Allele Genotyping in Critical Pharmacogenes Reduces Residual Clinical Risk in Diverse Populations.Semantic proximity Read ↗

Clinical Implications of Combinatorial Pharmacogenomic Tests Based on Cytochrome P450 Variant SelectionSemantic proximity Read ↗

Pharmacogenetic Panel Testing: A Review of Current Practice and Potential for Clinical ImplementationSemantic proximity Read ↗

Patterns of pharmacogenetic variation in nine biogeographic groups.Semantic proximity Read ↗

Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.Semantic proximity Read ↗

Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment.Semantic proximity Read ↗

Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process.Semantic proximity Read ↗

Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.Semantic proximity Read ↗

Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study.Semantic proximity Read ↗

The Value of Clinical Pharmacogenomic Guidelines That Recommend Standard of Care Over Genotype-Based Prescribing.Semantic proximity Read ↗

Pharmacogenomics in the era of next generation sequencing – from byte to bedsideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.